Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | VERV | Series A Convertible Preferred Stock | Jun 16, 2021 | Common Stock | 768K | See Footnotes | F1, F3, F4, F5 | |||||||
holding | VERV | Series A Convertible Preferred Stock | Jun 16, 2021 | Common Stock | 768K | See Footnotes | F2, F3, F4, F5 | |||||||
holding | VERV | Series A-2 Convertible Preferred Stock | Jun 16, 2021 | Common Stock | 487K | See Footnotes | F1, F3, F4, F5 | |||||||
holding | VERV | Series A-2 Convertible Preferred Stock | Jun 16, 2021 | Common Stock | 487K | See Footnotes | F2, F3, F4, F5 |
Id | Content |
---|---|
F1 | Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. |
F2 | Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. |
F3 | ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein. |
F4 | The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering. |
F5 | The expiration date is not relevant to the conversion of these securities. |
Exhibit 24 - Power of Attorney. Exhibit 24.1 - Power of Attorney